#1 Clinical Trials Search in Europe

Mesalazine

Mesalazine, also known as 5-aminosalicylic acid (5-ASA), is a medication widely studied in clinical trials for its effectiveness in treating inflammatory bowel diseases, particularly ulcerative colitis. This article explores various clinical trials investigating the use of mesalazine in different formulations and dosing regimens, as well as its potential benefits in managing symptoms, inducing remission, and improving quality of life for patients with these conditions.

Table of Contents

What is Mesalazine?

Mesalazine, also known as 5-aminosalicylic acid (5-ASA), is a medication primarily used to treat inflammatory bowel diseases[1]. It belongs to a class of drugs called aminosalicylates. Mesalazine is marketed under various brand names, including Asacol, Pentasa, and Lialda[2][2][2].

What Conditions Does Mesalazine Treat?

Mesalazine is primarily used to treat the following conditions:

  • Ulcerative Colitis (UC): This is a type of inflammatory bowel disease that causes inflammation and ulcers in the colon and rectum. Mesalazine is used for both inducing and maintaining remission in patients with mild to moderate UC[1][2].
  • Distal Ulcerative Colitis: This refers to inflammation limited to the lower part of the colon, including conditions like proctitis (inflammation of the rectum) and proctosigmoiditis (inflammation of the rectum and sigmoid colon)[3].
  • Crohn’s Disease: Although not explicitly mentioned in the provided trials, mesalazine is sometimes used in the treatment of Crohn’s disease, another type of inflammatory bowel disease.

How Does Mesalazine Work?

Mesalazine works by reducing inflammation in the intestines. While the exact mechanism is not fully understood, it is believed to work locally in the gut to decrease the production of chemicals that cause inflammation, such as prostaglandins and leukotrienes[2].

Interestingly, some research suggests that mesalazine may have additional beneficial effects. For example, one study is investigating whether mesalazine can induce the expression of certain genes (like μ-protocadherin) in the colon mucosa, which might help prevent colorectal cancer[4].

Dosage Forms and Administration

Mesalazine is available in various forms and dosages, including:

  • Tablets: These come in different strengths, such as 400 mg, 800 mg, and 1.2 g[2][2].
  • Extended-release tablets: These are designed to release the medication slowly throughout the digestive tract[2].
  • Suppositories and enemas: These forms are used for treating inflammation in the lower part of the colon and rectum.

The dosing regimen can vary depending on the specific condition being treated, the severity of the disease, and the individual patient. For example:

  • For maintaining remission in ulcerative colitis, a common dosage is 2.4 g per day, which can be taken as a single daily dose or divided into multiple doses[1][5].
  • For active mild to moderate ulcerative colitis, higher doses may be used for inducing remission[6].

Effectiveness of Mesalazine

Mesalazine has been shown to be effective in treating ulcerative colitis and maintaining remission. Clinical trials have evaluated its effectiveness using various measures:

  • Clinical remission: This is often measured using scoring systems like the Mayo Score or the Simple Clinical Colitis Activity Index (SCCAI)[1][6].
  • Endoscopic remission: This involves examining the lining of the colon using a camera (endoscopy) to assess healing[1][6].
  • Histological remission: This involves examining tissue samples under a microscope to assess inflammation at a cellular level[6].
  • Quality of life: Some studies have looked at how mesalazine treatment affects patients’ overall well-being and daily functioning[1][3].

Potential Side Effects

While mesalazine is generally well-tolerated, like all medications, it can cause side effects. Common side effects may include:

  • Headache
  • Nausea
  • Abdominal pain
  • Diarrhea

More serious side effects are rare but can include allergic reactions, kidney problems, or liver problems. It’s important to discuss any side effects with your healthcare provider[6].

Ongoing Research and Future Prospects

Research on mesalazine is ongoing, with studies exploring various aspects of its use:

  • Dosing regimens: Studies are comparing different dosing schedules (e.g., once daily vs. multiple times daily) to optimize effectiveness and patient adherence[1][5].
  • Long-term effects: Researchers are investigating the long-term safety and effectiveness of mesalazine in maintaining remission[5].
  • Cancer prevention: Some studies are exploring whether mesalazine might help prevent colorectal cancer in patients with ulcerative colitis[4].
  • Other conditions: Interestingly, one study is investigating whether mesalazine might help reduce immune activation in HIV patients, potentially offering benefits beyond its traditional use in inflammatory bowel diseases[7].

As research continues, our understanding of mesalazine and its potential uses may expand, potentially leading to improved treatments for patients with inflammatory bowel diseases and possibly other conditions.

Aspect Details
Primary Uses Treatment of ulcerative colitis, maintenance of remission
Formulations Tablets (e.g., Asacol, Pentasa, Lialda), various dosages
Dosing Regimens Once daily (e.g., 1600 mg, 2.4 g) or multiple daily doses
Key Outcomes Measured Clinical remission, endoscopic remission, quality of life, disease activity scores
Safety Assessments Adverse events, laboratory results, vital signs, physical examination findings
Additional Research Areas Potential use in reducing immune activation in HIV patients

FAQ

  • What is mesalazine used for in clinical trials? Mesalazine is primarily studied for its effectiveness in treating inflammatory bowel diseases, especially ulcerative colitis. Clinical trials investigate its use in inducing and maintaining remission, improving symptoms, and enhancing quality of life for patients with these conditions.
  • How is mesalazine administered in clinical trials? Mesalazine is administered in various forms and dosing regimens in clinical trials. Some studies explore once-daily dosing (e.g., 1600 mg or 2.4 g), while others investigate multiple daily doses. Different formulations such as tablets (e.g., Asacol, Pentasa, Lialda) are used to study the drug's effectiveness and patient adherence.
  • What are some of the outcomes measured in mesalazine clinical trials? Clinical trials measuring mesalazine's effectiveness often assess outcomes such as clinical remission, endoscopic remission, histological remission, quality of life improvements, changes in disease activity scores (e.g., Mayo Score), and markers of inflammation like fecal calprotectin.
  • Are there any potential side effects of mesalazine studied in clinical trials? While mesalazine is generally considered safe, clinical trials also evaluate its safety profile. Researchers monitor for adverse events, changes in laboratory results, vital signs, and physical examination findings. Some studies specifically assess the drug's tolerability and reasons for patient withdrawal due to safety concerns.
  • Can mesalazine be used for conditions other than inflammatory bowel diseases? While mesalazine is primarily studied for inflammatory bowel diseases, some clinical trials explore its potential in other conditions. For example, one study investigated its use in reducing residual systemic immune activation in treated HIV infection, suggesting potential applications beyond gastrointestinal disorders.

Ongoing Clinical Trials on Mesalazine

  • Study on Mesalamine to Prevent Colorectal Cancer in Patients with Lynch Syndrome

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Sweden

  • Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients with Ulcerative Colitis in Long-Term Remission

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Mesalazine: Also known as 5-aminosalicylic acid (5-ASA), it is a medication used to treat inflammatory bowel diseases, particularly ulcerative colitis.
  • Ulcerative Colitis: A chronic inflammatory bowel disease that affects the lining of the large intestine (colon) and rectum, causing inflammation and ulcers.
  • Remission: A period in the course of a disease when symptoms become less severe or disappear.
  • Mayo Score: A scoring system used to assess the severity of ulcerative colitis, considering factors such as stool frequency, rectal bleeding, and endoscopic findings.
  • Endoscopic Remission: The absence or significant reduction of visible inflammation in the intestinal lining when examined through an endoscope.
  • Histological Remission: The absence of microscopic inflammation in tissue samples taken from the intestinal lining.
  • Fecal Calprotectin: A protein found in stool samples that serves as a marker of intestinal inflammation.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • AUC24: Area Under the Curve from 0 to 24 hours, a measure used in pharmacokinetics to assess drug exposure over time.
  • Adherence: The extent to which a patient follows the prescribed treatment regimen, including taking medication as directed.

References

  1. https://clinicaltrials.gov/study/NCT04133194
  2. https://clinicaltrials.gov/study/NCT00751699
  3. https://clinicaltrials.gov/study/NCT02368743
  4. https://clinicaltrials.gov/study/NCT02077777
  5. https://clinicaltrials.gov/study/NCT00708656
  6. https://clinicaltrials.gov/study/NCT06176560
  7. https://clinicaltrials.gov/study/NCT03399903